# Tango Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tango-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.tangotx.com
- Total disclosed funding: $115M
- Latest round: Series B (Apr 9, 2020)
- Investors on record: 4

## About

Tango Therapeutics, Inc., based in the US, focuses on developing innovative cancer therapies through the principle of synthetic lethality, aiming to enhance treatment outcomes for patients with specific tumor profiles.Tango Therapeutics, Inc. is dedicated to advancing cancer therapies via synthetic lethality. Founded in 2017, the company is headquartered in Cambridge, US. Tim Lu serves as the founder, and Barbara Weber is the current CEO. Tango has successfully completed five deals, with its most recent funding round being a PIPE in August 2023, raising USD 80 mn led by Nextech, alongside other investors. The total amount raised to date is USD 80 mn.Tango Therapeutics specializes in developing therapies that leverage synthetic lethality to target specific tumors, addressing critical needs in oncology. Their offerings include genetically targeted therapies aimed at improving cancer treatment outcomes, serving healthcare providers like oncologists and hospitals across North America and Europe, which have a significant demand for such innovative therapies.In the most recent fiscal year, 2024, Tango Therapeutics reported revenue of USD 42.07 mn, while the EBITDA stood at USD -143.10 mn. The company generates revenue through strategic partnerships and collaborations focused on commercializing its synthetic lethality therapies, including shared development costs, milestone payments, and licensing agreements for its proprietary technologies.Following its recent PIPE funding round in August 2023, where Tango Therapeutics raised USD 80 mn, the company plans to use these funds to expand its programs across multiple tumor types. This strategic initiative may include the development and launch of new products targeting specific cancers. Moreover, Tango aims to enhance its presence in new markets, particularly focusing on North America and Europe, where the need for innovative cancer therapies is increasing.

## Funding rounds

- Series B, Apr 9, 2020, $60M — Casdin Capital, Cormorant Asset Management, Boxer Capital
- Series A, Mar 30, 2017, $55M — Third Rock Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B